J&J is back on the menu

After 10 days, the pause on the J&J vaccine has been lifted. According to CDC Director Rochelle Walensky, there have been about 1.9 cases of severe blood clotting per million people who had received the J&J vaccine. It has been re-authorized for use in people aged 18 and older, now with an addendum to the label and fact sheet warning of the risk of blood clots: 

It’s important to note that at time of writing (April 24) only some states have already resumed its use. (These are Arizona, Colorado, Connecticut, Louisiana, Maine, Massachusetts, Michigan, Missouri, Nevada, New York, Tennessee, Texas, Indiana, and Virginia.) However, this is coinciding with a larger trend of states ordering fewer vaccine doses.

The J&J vaccine’s return is probably good news for the rest of the world as well. Combined with the AstraZeneca vaccine, the J&J vaccine was supposed to be one of the big players in the global fight against COVID-19. But the U.S. pause raised concerns for vaccine diplomacy and the global rollout—J&J had also paused its European distribution, South Africa announced they were putting J&J distribution on a temporary hiatus, and Australia said it wouldn’t purchase any J&J doses. Resuming distribution in the U.S., which can act as a bellwether for which vaccines are seen as desirable abroad, might allay concerns about safety abroad.

More vaccine coverage

  • Sources and updates, November 12
    Sources and updates for the week of November 12 include new vaccination data, a rapid test receiving FDA approval, treatment guidelines, and more.
  • How is the CDC tracking the latest round of COVID-19 vaccines?
    Following the end of the federal public health emergency in May, the CDC has lost its authority to collect vaccination data from all state and local health agencies that keep immunization records. As a result, the CDC is no longer providing comprehensive vaccination numbers on its COVID-19 dashboards. But we still have some information about this year’s vaccination campaign, thanks to continued CDC efforts as well as reporting by other health agencies and research organizations.
  • Sources and updates, October 8
    Sources and updates for the week of October 8 include new papers about booster shot uptake, at-home tests, and Long COVID symptoms.
  • COVID source shout-out: Novavax’s booster is now available
    This week, the FDA authorized Novavax’s updated COVID-19 vaccine. Here’s why some people are excited to get Novavax’s vaccine this fall, as opposed to Pfizer’s or Moderna’s.

Leave a Reply